Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.
The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:
- KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
- KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
- KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
- KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.
Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.
Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.
For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.
Kymera Therapeutics (NASDAQ: KYMR) presented preclinical data on its IRAKIMiD and STAT3 protein degrader programs at the virtual 62nd ASH Annual Meeting. The IRAKIMiD candidate KT-413 showed significant anti-tumor activity in MYD88-mutant DLBCL models and is poised for a Phase 1 trial in 2H 2021. Additionally, the STAT3 degrader KTX-201 demonstrated potent cell killing in lymphoma models. These developments indicate promising next steps for advancing targeted therapies for severe blood cancers.
Kymera Therapeutics (NASDAQ: KYMR) announced that its Co-Founder, President, and CEO Nello Mainolfi, along with Chief Medical Officer Jared Gollob, will present at the Piper Sandler 32nd Annual Healthcare Conference taking place virtually from December 1 to December 3, 2020. A pre-recorded fireside chat will be available for viewing, accessible via the company's website. Kymera focuses on targeted protein degradation, aiming to develop treatments for immune-inflammatory diseases and cancers by utilizing the body’s protein recycling mechanisms.
Kymera Therapeutics (NASDAQ: KYMR) will be featured at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:00 a.m. ET. Nello Mainolfi, the Co-Founder, President, and CEO, will present the company’s innovative approach to targeted protein degradation.
This biopharmaceutical company focuses on harnessing the body's protein degradation system to develop treatments for immune-inflammatory diseases, hematologic malignancies, and solid tumors. A live webcast of the presentation can be accessed on their website, with an archived version available for 90 days.
Kymera Therapeutics (NASDAQ: KYMR) has reported significant advancements in its targeted protein degradation pipeline and financial results for Q3 2020. The company completed a successful IPO, raising approximately $213.3 million, and formed a strategic collaboration with Sanofi worth up to $2 billion. Positive interim results from a study on KT-474 (an IRAK4 degrader) in HS patients were also presented. The company aims to file IND applications for KT-474 and KT-413 (IRAKIMiD degrader) in 2021, while maintaining a strong cash position of $481.3 million, ensuring operational funding through 2025.
Kymera Therapeutics (NASDAQ: KYMR) announced the presentation of new preclinical data for its IRAKIMiD and STAT3 degrader programs at the 62nd American Society of Hematology Annual Meeting from December 5-8, 2020. Key findings include KT-413's efficacy in MYD88-mutant DLBCL models, showing deep tumor regressions with intermittent dosing. The STAT3 program also demonstrated tumor regressions in ALK+ ALCL. These results highlight the therapeutic potential of Kymera's targeted protein degradation approach to treat hematologic cancers effectively.
Kymera Therapeutics (NASDAQ: KYMR) is set to present key findings at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15. CEO Nello Mainolfi will deliver a keynote on the IRAK4 program and its role in treating conditions like hidradenitis suppurativa (HS) and atopic dermatitis (AD). The company emphasizes its innovative Pegasus platform, showcasing preclinical studies on pharmacokinetic/pharmacodynamic (PK/PD) relationships essential for clinical drug development. Significant results include elevated IRAK4 levels in diseased skin, highlighting the pathway's relevance in HS.
Kymera Therapeutics (NASDAQ: KYMR) presented interim data at the 5th Annual Symposium on Hidradenitis Suppurativa Advances, revealing insights from a non-interventional trial on IRAK4 expression in patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). The study highlighted the effectiveness of KT-474, an IRAK4-targeted protein degrader, in lowering IRAK4 levels in blood mononuclear cells. With a Phase 1 trial expected to start in 2021, these findings support the potential of IRAK4 degraders in treating HS and other inflammatory diseases, addressing a critical unmet medical need.
Kymera Therapeutics, a biopharmaceutical company focused on targeted protein degradation, announced that CEO Nello Mainolfi will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 5:00 p.m. ET. The presentation can be accessed via a live webcast on the company's website, with an archived version available for 90 days. Kymera's focus includes developing therapeutics that target difficult disease-causing proteins, specifically through its Pegasus platform, addressing immune-inflammatory diseases and tumors.
Kymera Therapeutics (NASDAQ: KYMR) announced the appointment of Pamela Esposito, PhD, and Jeff Albers, JD, to its Board of Directors. Both bring extensive biopharmaceutical experience, enhancing Kymera's leadership during a pivotal growth phase. Dr. Esposito has been instrumental in raising over $400M for Replimune's oncolytic therapies, while Albers led Blueprint Medicines through a successful IPO. Their expertise is expected to advance Kymera's strategic direction and innovative treatment options for cancer and autoimmune diseases.
Kymera Therapeutics (NASDAQ: KYMR) announced the closing of its upsized initial public offering, selling 9,987,520 common shares at $20.00 per share, yielding approximately $199.8 million in gross proceeds. This includes 1,302,720 shares purchased by underwriters' option. Additionally, Kymera completed a private placement of 676,354 shares to Vertex Pharmaceuticals, raising $13.5 million. Registration statements for these offerings were effective as of August 20, 2020. All shares were sold by Kymera, aimed at advancing targeted protein degradation therapeutics.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
What is Kymera Therapeutics' main focus?
What is the Pegasus platform?
What are some key drugs in Kymera's pipeline?
What diseases is Kymera targeting?
What recent achievements has Kymera made?
How does Kymera's technology differ from conventional therapies?
Who are Kymera's partners?
Where is Kymera Therapeutics headquartered?
How is Kymera funded?
Where can I find more information about Kymera?
